Insider · CIK 0002005407
ForGrowth NAP B.V.
owner
Files at NAMS (NewAmsterdam Pharma Co N.V.). First filing Nov 15, 2024, latest Jan 2, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $30M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NAMS: NewAmsterdam Pharma Co N.V.
NAMSOct 9, 2026 · close 21.58
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | NewAmsterdam Pharma Co N.V. | $762k 29,846 shares | -0% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $1.9M 74,910 shares | -1% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $2.3M 91,068 shares | -1% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $4.1M 157,234 shares | -1% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $3.0M 115,480 shares | -1% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $4.9M 191,762 shares | -2% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $12M 462,288 shares | -4% | - | |
| 17Weak | NewAmsterdam Pharma Co N.V. | $1.0M 41,803 shares | -0% | - | |
| 5Weak | NewAmsterdam Pharma Co N.V. | $273k 10,898 shares | -0% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -29,846 | $25.54 | $762k | 10,656,172 | Jan 2, 2025 |
| Dec 26, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -33,438 | $26.01 | $870k | 10,727,490 | Dec 30, 2024 |
| Dec 27, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -41,472 | $25.95 | $1.1M | 10,686,018 | Dec 30, 2024 |
| Dec 20, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -44,143 | $25.53 | $1.1M | 10,807,853 | Dec 26, 2024 |
| Dec 20, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -5,629 | $26.13 | $147k | 10,802,224 | Dec 26, 2024 |
| Dec 23, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -25,132 | $25.49 | $641k | 10,777,092 | Dec 26, 2024 |
| Dec 24, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -16,164 | $25.66 | $415k | 10,760,928 | Dec 26, 2024 |
| Dec 18, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -54,518 | $25.72 | $1.4M | 10,954,712 | Dec 20, 2024 |
| Dec 18, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -46,210 | $26.55 | $1.2M | 10,908,502 | Dec 20, 2024 |
| Dec 19, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -56,506 | $25.45 | $1.4M | 10,851,996 | Dec 20, 2024 |
| Dec 16, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -1,096 | $25.00 | $27k | 11,123,614 | Dec 18, 2024 |
| Dec 17, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -66,648 | $25.60 | $1.7M | 11,056,966 | Dec 18, 2024 |
| Dec 17, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -47,736 | $26.45 | $1.3M | 11,009,230 | Dec 18, 2024 |
| Dec 12, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -140,048 | $25.25 | $3.5M | 11,176,424 | Dec 16, 2024 |
| Dec 12, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -25,963 | $26.18 | $680k | 11,150,461 | Dec 16, 2024 |
| Dec 13, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -25,751 | $25.01 | $644k | 11,124,710 | Dec 16, 2024 |
| Dec 10, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -259,739 | $25.22 | $6.6M | 11,519,021 | Dec 12, 2024 |
| Dec 10, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -48,511 | $26.15 | $1.3M | 11,470,510 | Dec 12, 2024 |
| Dec 11, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -130,561 | $25.26 | $3.3M | 11,339,949 | Dec 12, 2024 |
| Dec 11, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -18,583 | $26.41 | $491k | 11,321,366 | Dec 12, 2024 |
| Dec 11, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -4,894 | $27.11 | $133k | 11,316,472 | Dec 12, 2024 |
| Nov 15, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -8,530 | $25.02 | $213k | 11,812,033 | Nov 19, 2024 |
| Nov 18, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -33,273 | $25.08 | $834k | 11,778,760 | Nov 19, 2024 |
| Nov 13, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -1,066 | $25.00 | $27k | 11,830,395 | Nov 15, 2024 |
| Nov 14, 2024 | NAMS NewAmsterdam Pharma Co N.V. | SOpen-market sale Ordinary Sharesindirect: See footnote10b5-1 | -9,832 | $25.01 | $246k | 11,820,563 | Nov 15, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.